Welcome to our dedicated page for RVL Pharmaceuticals plc news (Ticker: RVLP), a resource for investors and traders seeking the latest updates and insights on RVL Pharmaceuticals plc stock.
RVL Pharmaceuticals plc (RVLP) drives innovation in specialty ophthalmology and neurology treatments, most notably through its groundbreaking product UPNEEQ® – the first FDA-approved non-surgical solution for acquired blepharoptosis. This page serves as the definitive source for official company announcements, financial disclosures, and therapeutic developments.
Investors and industry professionals will find timely updates on regulatory milestones, clinical advancements, and corporate strategy. Our curated news collection includes earnings reports, partnership announcements, and progress updates on neurology-focused therapies for conditions like multiple sclerosis and Parkinson's disease.
Key areas of coverage include UPNEEQ® market adoption, Osmodex® technology applications, and strategic shareholder initiatives. All content is sourced directly from RVL Pharmaceuticals' verified communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to RVLP's latest press releases and financial presentations. Check back regularly for updates on pharmaceutical innovations that combine clinical expertise with patient-centric solutions.
RVL Pharmaceuticals plc (Nasdaq: RVLP) reported preliminary first quarter 2022 net sales of UPNEEQ at approximately $5.9 million, marking a 90% increase from Q4 2021. The company reaffirms its fourth quarter 2022 sales guidance of $20 to 25 million. UPNEEQ, the first FDA-approved ophthalmic solution for blepharoptosis, received a ‘Best in Innovation’ award from New Beauty. CEO Brian Markison highlighted strong sales momentum and growing interest from medical aesthetic practices, indicating significant market potential for UPNEEQ.
RVL Pharmaceuticals reported fourth quarter 2021 UPNEEQ sales of $3.1 million, a 39% increase over Q3. Full year revenues reached $17.5 million, reflecting a 37% decline compared to 2020. The company anticipates Q1 2022 UPNEEQ sales between $5.5 - 6.0 million and reaffirmed Q4 2022 guidance at $20 - 25 million. A recent license agreement amendment is expected to generate $20 million in non-dilutive funding. The net loss narrowed to $19.7 million from $51.8 million in Q4 2020, while adjusted EBITDA loss improved to $15.2 million.
RVL Pharmaceuticals plc will announce its 2021 Q4 and full-year financial results on March 30, 2022, after U.S. market close. The Company will also provide updates on its first-quarter 2022 Medical Aesthetic launch. The conference call with key executives will be held at 4:30 p.m. ET on the same day. RVL is focused on developing products for underserved patient populations, currently commercializing UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%. For further details, investors can visit the Company's website.
RVL Pharmaceuticals plc (Nasdaq: RVLP), a specialty pharmaceutical company, announced its participation in the Barclays Global Healthcare Conference 2022. Key executives, including CEO Brian Markison, COO James Schaub, and CFO Andrew Einhorn, will present on March 16, 2022, at 11:15 a.m. ET. The presentation will be available via a webcast, accessible on the company’s website afterward. RVL focuses on developing products for underserved patient populations, with a subsidiary dedicated to ophthalmic and medical aesthetics.
FAQ
What is the market cap of RVL Pharmaceuticals plc (RVLP)?
